Sarcoma  >>  Recentin (cediranib) 
Welcome,         Profile    Billing    Logout  

7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recentin (cediranib) / AstraZeneca
ACTRN12612000020886: A trial of cediranib in the treatment of patients with alveolar soft part sarcoma

Recruiting
2
36
 
The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK), Cancer Research UK, AstraZeneca
Alveolar soft part sarcoma
 
 
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy?

Not yet recruiting
2
129
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The University of Manchester, AstraZeneca Ltd
Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04]
 
 
NCT00942877: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Checkmark P2 data
May 2011 - May 2011: P2 data
Active, not recruiting
2
53
US
AZD2171, Cediranib
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
09/18
12/24
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, Sunitinib
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
SWOG S0905, NCT01064648: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting
1/2
117
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration
National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
06/18
03/25

Download Options